CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodu...
Saved in:
| Main Authors: | Tong Yu, Jian-Hang Jiao, Min-Fei Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499590/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01) -
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
by: Yuhan Hu, et al.
Published: (2025-03-01) -
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
by: Faroogh Marofi, et al.
Published: (2021-03-01) -
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01) -
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01)